Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Palisade Bio Inc
Healthcare
P/NCAV
0.25x
Ticker
PALI
Exchange
NASDAQ
Country
United States
Close
5.92 $
Mkt Cap
2.7M $
EV
-9.6M $
NCAV Burn Rate
7.5%
Current Ratio
5.15
Debt/Equity
0.01
EV/REV
-38.3x
EV/EBIT
0.7x
EV/FCF
0.9x
Dilution
165.2% p.A
Total Net Income
-163.0M $
Cheapness
88.0%
Palisade Bio, Inc. is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company’s approach is founded on the discovery that damage to the intestinal epithelial barrier can result in the leakage of digestive enzymes from the gastrointestinal (GI) tract into the peritoneal cavity, which can damage tissues and promote inflammation, causing a broad array of acute and chronic conditions. Its lead therapeutic candidate, LB1148, is an oral liquid formulation of the well-characterized digestive enzyme inhibitor tranexamic acid (TXA), which is being developed for administration prior to surgeries that are at risk of disrupting the intestinal epithelial barrier. LB1148 is formulated as an aqueous solution for oral (enteral) administration. In addition to TXA, the LB1148 formulation contains polyethylene glycol, carbohydrates, and electrolytes.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average